Patents by Inventor Doris Shim Siew Chen

Doris Shim Siew Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CXCR2 ANTIBODIES AND USES THEREOF
    Publication number: 20220348671
    Abstract: Disclosed herein are human antibody molecules that immunospecifically bind to human CXCR2. The disclosed human antibody molecules are potent and selective antagonists of CXCR2 functions and prevent the recruitment of neutrophils into tissues without strongly depleting circulating neutrophil numbers. Pharmaceutical compositions, nucleic acid molecules, vectors, cells, and uses of the disclosed antibodies are also provided.
    Type: Application
    Filed: April 12, 2022
    Publication date: November 3, 2022
    Inventors: Doris Shim Siew Chen, Lynn Dorothy Poulton, Adam Clarke, David Jose Simon Laine, Matthew Pollard, Bridget Ann Cooksey, Anthony Doyle, Jason William Gill
  • Anti-CXCR2 antibodies and uses thereof
    Patent number: 11332534
    Abstract: Disclosed herein are human antibody molecules that immunospecifically bind to human CXCR2. The disclosed human antibody molecules are potent and selective antagonists of CXCR2 functions and prevent the recruitment of neutrophils into tissues without strongly depleting circulating neutrophil numbers. Pharmaceutical compositions, nucleic acid molecules, vectors, cells, and uses of the disclosed antibodies are also provided.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: May 17, 2022
    Assignee: Cephalon, Inc.
    Inventors: Doris Shim Siew Chen, Lynn Dorothy Poulton, Adam Clarke, David Jose Simon Laine, Matthew Pollard, Bridget Ann Cooksey, Anthony Doyle, Jason William Gill
  • ANTI-CXCR2 ANTIBODIES AND USES THEREOF
    Publication number: 20200040089
    Abstract: Disclosed herein are human antibody molecules that immunospecifically bind to human CXCR2. The disclosed human antibody molecules are potent and selective antagonists of CXCR2 functions and prevent the recruitment of neutrophils into tissues without strongly depleting circulating neutrophil numbers. Pharmaceutical compositions, nucleic acid molecules, vectors, cells, and uses of the disclosed antibodies are also provided.
    Type: Application
    Filed: July 31, 2019
    Publication date: February 6, 2020
    Inventors: Doris Shim Siew Chen, Lynn Dorothy Poulton, Adam Clarke, David Jose Simon Laine, Matthew Pollard, Bridget Ann Cooksey, Anthony Doyle, Jason William Gill